46岁的深圳患者阿强在没有刻意减重的情况下体重骤降12斤，随后出现胸闷腹胀、酒量下降等症状，经检查确诊为中晚期肝癌1。其肿瘤超过12厘米，并毗邻重要血管，原本不具备手术条件1。
北京大学深圳医院肝胆胰外科多学科团队为阿强制定了转化治疗方案，采用经导管动脉化疗栓塞术联合靶向药物治疗1。经过两个月的治疗，肿瘤明显缩小，达到了手术指征1。2022年3月，医疗团队成功为患者实施腹腔镜肝癌根治术，病理检查结果显示实现了病理学完全缓解1。截至2026年8月，阿强已度过53个月的随访期，未出现复发迹象1。
根据国家癌症中心2024年数据，我国肝癌发病率在恶性肿瘤中居第5位，死亡率则高居第2位1。国内超过70%的肝癌患者确诊时已处于中晚期阶段，且近八成肝癌患者存在乙肝感染背景1。2026版国家原发性肝癌诊疗指南已将转化治疗列为核心更新内容1。
A 46-year-old Shenzhen resident identified as Aqiang was diagnosed with advanced-stage hepatocellular carcinoma in 2021 after experiencing a sudden 12-pound weight loss without intentional dieting, followed by chest tightness, abdominal distension, and reduced alcohol tolerance 1. Imaging revealed a tumor exceeding 12 centimeters in size that invaded critical blood vessels, initially rendering him ineligible for surgical intervention 1.
A multidisciplinary team at Peking University Shenzhen Hospital implemented a transformation therapy strategy combining transarterial chemoembolization with targeted pharmaceutical agents 1. Following two months of treatment, the tumor demonstrated significant shrinkage, allowing the patient to meet surgical criteria 1. In March 2022, the team successfully performed laparoscopic hepatic resection, with pathological examination confirming complete remission 1. As of August 2026, Aqiang has completed 53 months of follow-up surveillance without recurrence 1.
The case reflects broader epidemiological challenges in China, where hepatocellular carcinoma ranks fifth in malignancy incidence but second in mortality according to 2024 data from the National Cancer Center 1. Over 70 percent of domestic hepatocellular carcinoma patients present with advanced disease at diagnosis, and approximately 80 percent carry a background of hepatitis B infection 1. The 2026 edition of China's national guidelines for primary hepatocellular carcinoma diagnosis and treatment has incorporated transformation therapy as a core update 1.
评论
还没有评论，欢迎留下第一条。